- Guardant Health (GH, Financial) launches the Guardant360 Tissue, the first tissue molecular profiling test with comprehensive multiomic analysis.
- The test requires 92% less tissue surface area and 40% fewer slides than the industry norm.
- Guardant360 Tissue is covered by Medicare for eligible patients, with results available in less than two weeks.
Guardant Health, Inc. (GH), a leader in precision oncology, announced the introduction of Guardant360® Tissue, the first tumor tissue molecular profiling test that integrates comprehensive multiomics analysis, including DNA, RNA, AI-powered PD-L1, and exome-wide methylation data. This innovation provides researchers and cancer care teams with a more holistic understanding of cancer.
Powered by the Guardant Infinityâ„¢ smart liquid biopsy platform, the advanced Guardant360 Tissue test reveals insights beyond traditional methods by incorporating extensive epigenetic analysis. This could significantly impact the use of therapeutics such as PARP-inhibitors and immunotherapies, as well as emerging therapies in development stages.
The test uniquely requires 92% less tissue surface area for analysis compared to the industry standard, allowing for broader applicability and testing opportunities, with the use of 40% fewer slides. This approach enables access to a larger patient pool by maximizing the use of limited tissue samples.
Dr. Helmy Eltoukhy, chairman and co-CEO of Guardant Health, emphasized that the Guardant360 Tissue establishes a groundbreaking standard in tissue profiling, granting healthcare providers and researchers an unprecedented level of insight into individual tumors. The test is expected to foster improved clinical actionability and patient outcomes across Guardant Health's product lineup.
Guardant360 Tissue's molecular profiling capability analyzes 742 DNA genes and fusions in 367 RNA genes, and provides exome-wide analysis of the tumor methylome. The test results are available within two weeks and are covered by Medicare for eligible patients.
For more information about Guardant Health's initiatives in precision oncology, visit their official website or follow the company on social media platforms.
